The advancement of live microbiome therapies into later phase clinical trials has raised hopes of a near-future where we will be able to prevent or treat diseases by modulating the microbiome. While new companies are joining the microbiome industry each year, there is one barrier of entry that makes life in the industry as difficult as one can expect in an emerging field: regulatory uncertainty. This whitepaper reviews the current situation in two parts of the world where the microbiome industry is advancing fast, namely the US and the EU.
It looks at two case studies: the uncertain status of fecal microbiota transplantation (FMT) in the US and FMT under Gene, Cells, and Tissue Regulations in Europe.
To download simply log in or register for an Informa Connect account, which will give you access to all our exclusive premium content.
Have any questions or interested in sponsoring future content? Email andrew.burrows@informa.com.
Log in or Create an Informa Connect Account to Access this content
Creating an account also means you'll get special access to article updates and exclusive industry content.